Instrument Inactif

Communiqués Pandion Therapeutics, Inc.

Actions

PAND

US6983401067

Recherche biotechnologique et médicale

Communiqués

01/04/21	PANDION THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
12/03/21	PANDION THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
02/03/21	PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND	BU
25/02/21	PANDION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22/02/21	Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting	GL
18/02/21	Pandion Therapeutics : to Present at the 10th Annual SVB Leerink Global Healthcare Conference	AQ
04/01/21	PANDION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/01/21	Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells	GL
03/12/20	PANDION THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
03/12/20	Pandion Therapeutics Appoints Katina Dorton to its Board of Directors	GL
16/11/20	PANDION THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
16/11/20	Pandion Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Business Update	AQ
16/11/20	Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update	GL
10/11/20	Pandion Therapeutics : to Present at the Stifel 2020 Virtual Healthcare Conference	AQ
10/11/20	Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference	GL
28/10/20	Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020	GL
28/10/20	Pandion Therapeutics : Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020	AQ
24/09/20	Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit	GL
24/09/20	Pandion Therapeutics : to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit	AQ
10/09/20	Pandion Therapeutics : to Present at Morgan Stanley Global Healthcare Conference	AQ
10/09/20	Pandion Therapeutics to Present at Morgan Stanley Global Healthcare Conference	GL
31/08/20	Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update	GL
17/07/20	Pandion Therapeutics Announces Pricing of Initial Public Offering	GL